Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia

Eur Heart J.

Tada H,Kawashiri M, Nohara A, Inazu A, Mabuchi H, Yamagishi M

doi: 10.1093/eurheartj/ehx004.

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study

Circulation.

Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman DM, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA

doi: 10.1161/CIRCULATIONAHA.

RECOMMENDED

Cardiovascular Risk and Diseases

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Lancet

EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

doi: 10.1016/S0140-6736(21)01122-3

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Lancet Diabetes Endocrinol.

Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA

doi: 10.1016/S2213-8587

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs

Statins for children with familial hypercholesterolemia

Cochrane Database Syst Rev.

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U

doi: 10.1002/14651858.

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia

Eur Heart J Cardiovasc Imaging.

Miname MH, Bittencourt MS, Pereira AC, Jannes CE, Krieger JE, Nasir K, Santos RD

doi: 10.1093/ehjci/jez280.

RECOMMENDED

Heart, Artery and Coronary Diseases

Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Atherosclerosis.

Gulizia MM, Maggioni AP, Abrignani MG, Bilato C, Mangiacapra F, Sanchez FA, Piovaccari G, Montagna L, Marini M, De Biasio M, Averna M, Casula M, Colivicchi F, Fabbri G, Lucci D, Zampoleri V, Catapano AL, POSTER Investigators

doi: 10.1016/j.atherosclerosis.2020.07.007.

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis

Eur Heart J

Marquina C, Lacaze P, Tiller J, Riaz M, Sturm AC, Nelson MR, Ference BA, Pang J, Watts GF, Nicholls SJ, Zoungas S, Liew D, McNeil J, Ademi Z

doi: 10.1093/eurheartj/ehab770

Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.

Eur Heart J.

Langslet G

doi: 10.1093/eurheartj/ehw098.

Related content

Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia

Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Statins for children with familial hypercholesterolemia

Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia

Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study

Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis

Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.